trending Market Intelligence /marketintelligence/en/news-insights/trending/VfMSuqkiSdAN9QR5923U-w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Capricor halts Duchenne drug trial after patient suffers allergic reaction

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Capricor halts Duchenne drug trial after patient suffers allergic reaction

California-based drugmaker Capricor Therapeutics Inc. voluntarily halted testing of its Duchenne muscular dystrophy treatment after a patient had a severe allergic reaction during the trial.

Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness that could lead to death.

Capricor said the patient responded well to medical treatment and is now showing no symptoms.

The trial, dubbed Hope-2, was evaluating Capricor's experimental drug CAP-1002 in young men and boys. The treatment received the U.S. Food and Drug Administration's regenerative medicine advanced therapy designation in February and has also received the FDA's orphan drug and rare pediatric disease designations in the past.

Capricor notified the FDA of the issue and is working with the regulator on a mitigation plan.